近日，佛羅里達州梅奧診所的研究人員發(fā)現(xiàn)現(xiàn)今普遍認為的一種能抑制癌細胞生長的分子實際上有助于致命甲狀腺腫瘤的生長,，相關研究論文發(fā)表在Journal of Cell Science雜志上。
研究發(fā)現(xiàn),，在未分化甲狀腺癌中,，F(xiàn)OXO3a轉(zhuǎn)錄因子不抑制促癌基因，而是致命腫瘤的生長刺激因子,。在人類未分化甲狀腺癌的實驗室模型中,，F(xiàn)OXO3a沉默后，腫瘤細胞生長緩慢,，但是當它重新恢復表達時,，腫瘤細胞會生長得更快。
FOXO3a是一已知的腫瘤生長抑制因子,，因為其能通過開啟細胞核內(nèi)的基因,、觸發(fā)細胞死亡來響應所有細胞應激形式。癌癥,，反過來通過將FOXO3a出核,，進入細胞質(zhì)中來關閉FOXO3a。促進FOXO3a出核的分子是Akt,，Akt促使癌癥細胞存活,。
該研究小組利用Akt蛋白受體阻滯劑來增加核中FOXO3a，抑制未分化甲狀腺癌細胞的生長,。
研究表明Akt抑制劑的使用將FOXO3a保持在細胞核中,，幫助殺死癌細胞，而FOXO3a本身不加速腫瘤細胞的成長。（生物谷：Bioon.com）
doi:10.1242/jcs.097428
PMC:
PMID:
Foxo3a drives proliferation in anaplastic thyroid carcinoma via transcriptional regulation of cyclin A1: A paradigm shift that impacts current therapeutic strategies
Laura A. Marlow, Christina A. von Roemeling, Simon J. Cooper, Yilin Zhang, Stephen D. Rohl, Shilpi Arora, Irma M. Gonzales, et al.
The Forkhead transcription factor, FoxO3a, is a known suppressor of primary tumor growth via transcriptional regulation of key genes regulating cell cycle arrest and apoptosis. In many types of cancer, in response to growth factor signaling, FoxO3a is phosphorylated by Akt, resulting in its exclusion from the nucleus. Here we show that FoxO3a remains nuclear in anaplastic thyroid carcinoma (ATC). This correlates with lack of Akt phosphorylation at S473 in ATC cell lines and patient ATC tissues, providing a potential explanation for nuclear FoxO3a. Mechanistically, nuclear FoxO3a promotes cell cycle progression by transcriptional upregulation of cyclin A1, promoting proliferation of human ATC cells. Silencing FoxO3a with a reverse genetics approach leads to down-regulation of CCNA1 mRNA and protein. This combined data implicates an entirely novel function for FoxO3a in ATC promotion by enhancing cell cycle progression and tumor growth via transcriptional upregulation of cyclin A1. This is clinically relevant since we detected highly elevated CCNA1 mRNA and protein levels in ATC patient tumor tissues. Our data indicate therapeutic inactivation of FoxO3a may lead to attenuation of tumor expansion in ATC. This new paradigm also suggests caution related to current dogma focused upon reactivation of FoxO3a as a therapeutic strategy against cancers harboring active PI3-K and Akt signaling pathways.
